TherapeuticsMD (TXMD) Given a $10.00 Price Target by Oppenheimer Analysts

TherapeuticsMD (NASDAQ:TXMD) received a $10.00 price target from stock analysts at Oppenheimer in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 88.32% from the company’s previous close.

TXMD has been the topic of several other reports. BidaskClub raised TherapeuticsMD from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 25th. Cantor Fitzgerald reissued a “buy” rating and set a $28.00 price target on shares of TherapeuticsMD in a report on Sunday, January 7th. Zacks Investment Research cut TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Friday, January 12th. Cowen reissued an “outperform” rating and set a $16.00 price target (up from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. Finally, Deutsche Bank set a $9.00 price target on TherapeuticsMD and gave the company a “buy” rating in a report on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $14.50.

TherapeuticsMD (TXMD) opened at $5.31 on Wednesday. The firm has a market capitalization of $1,207.51, a price-to-earnings ratio of -13.27 and a beta of 1.23. TherapeuticsMD has a twelve month low of $3.50 and a twelve month high of $8.30.

In related news, Director Tommy G. Thompson bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were bought at an average cost of $6.21 per share, with a total value of $31,050.00. Following the acquisition, the director now owns 3,555 shares in the company, valued at $22,076.55. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 23.92% of the stock is owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. MANA Advisors LLC bought a new position in TherapeuticsMD in the 4th quarter worth $104,000. Paloma Partners Management Co bought a new position in TherapeuticsMD in the 4th quarter worth $105,000. Edge Wealth Management LLC raised its holdings in TherapeuticsMD by 2,500.0% in the 4th quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock worth $125,000 after purchasing an additional 20,000 shares during the period. Virtu KCG Holdings LLC bought a new position in TherapeuticsMD in the 2nd quarter worth $157,000. Finally, Quantbot Technologies LP bought a new position in TherapeuticsMD in the 3rd quarter worth $189,000. 71.40% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This piece was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply